Tokyo, Mar 30, 2006 (JCN) - Santen Pharmaceutical has signed a licensing agreement with Oakwood of Ohio for the development of the microsphere formulation of a steroid (DE-102) for diabetic macular edema (DME), a kind of diabetic complication that may induce visual impairment and blindness.
